Clinical Trial Update: Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease [Phase 1]

View source ↗

Summary

Phase 1 trial update of ultra-low dose interleukin-2 for refractory chronic graft versus host disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Interleukin-2 (interleukin-2)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Graft Versus Host Disease | Phase 1 | Status: COMPLETED | Results posted: 2014-01-29